Product Description
Clevidipine (Cleviprex), a late-generation dihydropyridine calcium channel antagonist available as a lipid emulsion for intravenous infusion, is approved in the US for the reduction of blood pressure (BP) when oral therapy is not feasible or desirable. Intravenous clevidipine is effective in the treatment of both acute preoperative and postoperative hypertension in adult cardiac surgery patients, and with a rapid onset and short duration of action the drug can be easily titrated for predictable BP control. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/19331440/)
Mechanisms of Action: Calcium Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Canada | France | Germany | Italy | Luxembourg | Netherlands | New Zealand | Spain | Sweden | Switzerland | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, Unknown Location
Active Clinical Trial Count: 11
Highest Development Phases
Phase 3: Hypertension|Hypertension, Malignant
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| HC1902-002 | P3 |
Not yet recruiting |
Hypertension, Malignant |
2024-12-01 |
82% |
| QLG2071-301 | P3 |
Not yet recruiting |
Hypertension, Malignant |
2024-05-24 |
82% |
| CTR20210819 | P3 |
Completed |
Hypertension |
2023-08-22 |
|
| CTR20212877 | P3 |
Completed |
Unknown |
2022-12-02 |